Advances in Cellular and Molecular Treatment of Autoimmune Diseases
A special issue of Cells (ISSN 2073-4409). This special issue belongs to the section "Cellular Immunology".
Deadline for manuscript submissions: closed (30 September 2024) | Viewed by 17325
Special Issue Editors
Interests: rheumatoid arthritis; tumor necrosis factor; fatty acids; treatment; systemic lupus erythematosus
Special Issues, Collections and Topics in MDPI journals
Interests: autoimmunity; autoimmune diseases; diet; immunosuppression; immunoregulation; microbiome; nutrition; rheumatic diseases
Special Issues, Collections and Topics in MDPI journals
Interests: rheumatoid arthritis; diabetes mellitus; oncology
Special Issues, Collections and Topics in MDPI journals
Special Issue Information
Dear Colleagues,
Lately, there is a world-wide increase in the prevalence and incidence of autoimmune diseases. Hence, extensive research is performed in order the identify causes and risk factors of autoimmune diseases. Extensive research in the pathophysiology of autoimmune diseases has revealed the implication of various factors in their pathogenesis. Treatment of autoimmune diseases has been the subject of fruitful research in recent years. Corticosteroids may be applied as early treatment. Disease modifying non-biologic drugs such as methotrexate, leflunomide, sulfasalazine and hydroxychloroquine have been used and may alter disease prognosis. Biologic agents targeting cellular and molecular targets have been introduced in the treatment of autoimmune diseases and have induced disease remission and may have altered disease progression and long-term disease prognosis. Biologic agents may be used either intravenously or subcutaneously. However, biologic agents are related with a high cost. Therefore, biosimilars of these agents have been introduced in the treatment of autoimmune diseases. The concurrent application of non-biologic disease modifying agents and biologics is discussed. Currently, there is availability of diverse effective agents targeting cellular and molecular targets in the treatment of autoimmune diseases and has enabled the modification of treatment regimens to the needs of each individual patient.
Dr. Panagiotis Athanassiou
Prof. Dr. Dimitrios P. Bogdanos
Dr. Ifigenia Kostoglou-Athanassiou
Guest Editors
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cells is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2700 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- autoimmune diseases
- disease activity
- TNFa inhibitors
- tocilizumab
- infliximab
- golimumab
- etanercept
- JAK inhibitors
- cellular targets
- molecular targets
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.
Further information on MDPI's Special Issue polices can be found here.